PE20020802A1 - COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE - Google Patents

COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE

Info

Publication number
PE20020802A1
PE20020802A1 PE2001001142A PE2001001142A PE20020802A1 PE 20020802 A1 PE20020802 A1 PE 20020802A1 PE 2001001142 A PE2001001142 A PE 2001001142A PE 2001001142 A PE2001001142 A PE 2001001142A PE 20020802 A1 PE20020802 A1 PE 20020802A1
Authority
PE
Peru
Prior art keywords
inhibitor
release
amyloid peptide
lactam compound
compound
Prior art date
Application number
PE2001001142A
Other languages
English (en)
Inventor
James Edmund Audia
Varghese John
Stacey Leigh Mcdaniel
Eugene D Thorsett
Jay S Tung
Jeffrey Scott Nissen
Lee H Latimer
Original Assignee
Lilly Co Eli
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Elan Pharm Inc filed Critical Lilly Co Eli
Publication of PE20020802A1 publication Critical patent/PE20020802A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE AL COMPUESTO DE LACTAMA (N)-((S)-2-HIDROXI-3-METIL-BUTIRIL)-1-(L-ALANINIL)-(S)-1-AMINO-3-METIL-4,5,6,7-TETRAHIDRO-2H-3-BENZAZEPIN-2-ONA COMO INHIBIDOR DE LA LIBERACION Y/O SINTESIS DEL PEPTIDO ß-AMILOIDE. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO PAR ALA PREPARACION. EL COMPUESTO ES UTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
PE2001001142A 2000-11-17 2001-11-16 COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE PE20020802A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17

Publications (1)

Publication Number Publication Date
PE20020802A1 true PE20020802A1 (es) 2002-09-10

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001142A PE20020802A1 (es) 2000-11-17 2001-11-16 COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE

Country Status (34)

Country Link
US (1) US20050261495A1 (es)
EP (1) EP1341531B1 (es)
JP (1) JP4116437B2 (es)
KR (1) KR100819679B1 (es)
CN (1) CN1486184A (es)
AR (1) AR035927A1 (es)
AU (2) AU2002243192B2 (es)
BR (1) BR0115427A (es)
CA (1) CA2427227C (es)
CY (1) CY1106366T1 (es)
CZ (1) CZ20031351A3 (es)
DE (1) DE60126132T2 (es)
DK (1) DK1341531T3 (es)
DZ (1) DZ3453A1 (es)
EA (1) EA005954B1 (es)
EC (1) ECSP034600A (es)
ES (1) ES2278804T3 (es)
HK (1) HK1059731A1 (es)
HR (1) HRP20030383B1 (es)
HU (1) HU228117B1 (es)
IL (2) IL155960A0 (es)
MX (1) MXPA03004292A (es)
MY (1) MY134559A (es)
NO (1) NO324324B1 (es)
NZ (1) NZ525854A (es)
PE (1) PE20020802A1 (es)
PL (1) PL212199B1 (es)
PT (1) PT1341531E (es)
SI (1) SI1341531T1 (es)
SK (1) SK288065B6 (es)
TW (1) TWI305204B (es)
UA (1) UA74849C2 (es)
WO (1) WO2002047671A2 (es)
ZA (1) ZA200303789B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
US8114886B2 (en) 2005-04-08 2012-02-14 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
JP5198877B2 (ja) * 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション ベンゾアゼピノン類の製造方法
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
EP2193117A1 (en) * 2007-07-16 2010-06-09 Wyeth a Corporation of the State of Delaware Inhibitors of beta amyloid production
KR101136260B1 (ko) 2007-08-14 2012-04-19 일라이 릴리 앤드 캄파니 감마-세크레타제 억제제로서의 아제핀 유도체
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
CA2709677C (en) 2007-12-21 2017-03-14 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
WO2014039781A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
JP6290237B2 (ja) 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための組成物および方法
AR094116A1 (es) 2012-12-20 2015-07-08 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de hdm2
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP4077282A4 (en) 2019-12-17 2023-11-08 Merck Sharp & Dohme LLC PRMT5 INHIBITORS
TW202423928A (zh) 2022-09-02 2024-06-16 美商默沙東有限責任公司 源自依克沙替康(exatecan)之拓樸異構酶-1抑制劑醫藥組合物及其用途
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
US20240207425A1 (en) 2022-12-14 2024-06-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319239T3 (es) * 1996-12-23 2009-05-05 Elan Pharmaceuticals, Inc. Cicloalquilo, lactama, lactona y compuestos relacionados, composiciones farmaceuticas que comprenden los mismos y procedimientos para inhibir la liberacion del peptido beta-amiloide y/o sintesis mediante el uso de tales compuestos.
AU4707999A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP2003513958A (ja) * 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
AU2002224322A1 (en) * 2000-11-17 2002-05-27 Eli Lilly And Company Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease

Also Published As

Publication number Publication date
JP2004517090A (ja) 2004-06-10
PL212199B1 (pl) 2012-08-31
KR20030051846A (ko) 2003-06-25
MXPA03004292A (es) 2004-02-12
WO2002047671A2 (en) 2002-06-20
EA200300580A1 (ru) 2003-10-30
DK1341531T3 (da) 2007-05-14
CY1106366T1 (el) 2011-10-12
HU228117B1 (en) 2012-11-28
CN1486184A (zh) 2004-03-31
CZ20031351A3 (cs) 2003-11-12
EA005954B1 (ru) 2005-08-25
TWI305204B (en) 2009-01-11
EP1341531A2 (en) 2003-09-10
SK5592003A3 (en) 2003-12-02
AU4319202A (en) 2002-06-24
JP4116437B2 (ja) 2008-07-09
SK288065B6 (sk) 2013-04-03
WO2002047671A3 (en) 2003-03-06
AR035927A1 (es) 2004-07-28
PT1341531E (pt) 2007-04-30
IL155960A0 (en) 2003-12-23
IL155960A (en) 2009-06-15
NZ525854A (en) 2004-06-25
CA2427227A1 (en) 2002-06-20
KR100819679B1 (ko) 2008-04-04
HK1059731A1 (en) 2004-07-16
ES2278804T3 (es) 2007-08-16
HRP20030383A2 (en) 2005-10-31
DE60126132D1 (de) 2007-03-08
NO20032236L (no) 2003-07-10
SI1341531T1 (sl) 2007-06-30
PL362688A1 (en) 2004-11-02
EP1341531B1 (en) 2007-01-17
UA74849C2 (en) 2006-02-15
HUP0301842A2 (hu) 2003-09-29
US20050261495A1 (en) 2005-11-24
HRP20030383B1 (en) 2007-12-31
BR0115427A (pt) 2003-10-07
MY134559A (en) 2007-12-31
ECSP034600A (es) 2003-06-25
NO324324B1 (no) 2007-09-24
CA2427227C (en) 2010-08-17
ZA200303789B (en) 2004-08-16
AU2002243192B2 (en) 2006-07-20
NO20032236D0 (no) 2003-05-16
DE60126132T2 (de) 2007-10-18
HUP0301842A3 (en) 2010-03-29
DZ3453A1 (fr) 2002-06-20

Similar Documents

Publication Publication Date Title
PE20020802A1 (es) COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
AR016751A1 (es) Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
PA8591701A1 (es) Derivados de pirrolopirimidina
CO5180579A1 (es) Composicion oral solida que comprende levidopa, carbidopa y entacapone
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
BR0211905A (pt) Dialdeìdos de rapamicina
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
EA200100519A1 (ru) Композиции на основе тонкоизмельченного эплеренона
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
UY26130A1 (es) Compuestos para tratar la obesidad
BRPI0418245B8 (pt) composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
AR029825A1 (es) Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma
AR025307A1 (es) Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
PA8581801A1 (es) Formulaciones que contienen un compuesto de indolinona
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
ECSP024389A (es) Composiciones farmaceuticas solidas de valsartan
SE9901077D0 (sv) Novel use
BR0115424A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
PE20021016A1 (es) Conjugados de pregabalina-lactosa
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ATE253359T1 (de) Antithrombotische mittel

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed